Stock Ratings / Health Care / DSGN / forecast

GYRE (47) WVE (22) APMD (44) ANL (47) ⌘ Pro Terminal →

Design Therapeutics Inc. (DSGN) 12-Month Stock Forecast & Price Target Cone

$10.68 -3.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.59

Design Therapeutics Inc. (DSGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $692.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DSGN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DSGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Design Therapeutics Inc. (NASDAQ: DSGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.68 (-3.44% 1D, market cap $692.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DSGN ranks #675 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DSGN compare to GYRE and WVE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DSGN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.1%. By comparison, GYRE (Gyre Therapeutics Inc.) holds a D grade (47/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M) and WVE (Wave Life Sciences Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DSGN?

▼

Per DSGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001807120), Design Therapeutics Inc. generated $0 in revenue, -$69.8M in net income, and -$54.6M in free cash flow against $226.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.59 (-0.81%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DSGN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY DSGN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (37% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.91-2.5% Next Q

Q2 (-2Q)

Grade D$10.64-2.8% Next Q

Q3 (-1Q)

Grade E$10.34+3.3% Next Q

Current

Grade D-$10.68-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DSGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DSGN currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.58) and Max Pain ($11.21) forces dealer call-delta covering toward $18.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DSGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DSGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your DSGN Position Size: $10,000

Shares at $10.68: 936.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $7.46

$6,985

$-3,015 (-30.1%)

12M Consensus BaseTarget $9.57

$8,961

$-1,039 (-10.4%)

12M Bull Case BreakoutTarget $18.11

$16,957

+$6,957 (+69.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$10	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$17	69%	B
JP MorganUS Large-Cap Research	SELL	$9	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DSGN)

✓Walkthrough of DSGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DSGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.91%📐 HORIZONTAL RANGE

2026-11-02O $11.08H $11.08L $10.68C $10.68VOL 276.6K

RES: $16.54SUP: $9.05SMA50: $12.58SMA200: $12.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DSGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DSGN Butterfly Map → + Track DSGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DSGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DSGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DSGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DSGN)

Health Care Rank #675 of 1016 ⚔️ GYRE vs DSGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DSGN vs. GYRE, WVE, APMD, ANL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Design Therapeutics Inc. (DSGN) ranks #675 by composite RQD confidence (35/100, grade D-) and #401 by equity capitalization ($692.2M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. GYRE currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with DSGN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DSGN ACTIVE Design Therapeutics Inc.	D-	35/100	—	—	-32.1%	-3.44%	$692.2M	Benchmark Subject
GYRE Gyre Therapeutics Inc.	D	47/100	72.3x	95.4%	25.4%	-28.94%	$714.8M	/gyre-vs-dsgn →
WVE Wave Life Sciences Inc.	E	22/100	—	—	-35.0%	-1.10%	$715.9M	/wve-vs-dsgn →
APMD Apnimed Inc.	D	44/100	—	—	—	-5.42%	$721.9M	/apmd-vs-dsgn →
ANL Adlai Nortye Group Ltd.	D	47/100	—	—	—	-7.10%	$662.0M	/anl-vs-dsgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001807120

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Design Therapeutics Inc. (DSGN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$69.8M, operating cash flow of -$54.4M, and free cash flow of -$54.6M (-25.6% YoY). On the balance sheet, DSGN closed FY2025 with $226.2M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$69.8M	-$54.4M	-$54.6M	$226.2M	—
FY2024 (FY)	2024-12-31	$0	-$49.6M	-$43.1M	-$43.4M	$252.1M	—
FY2023 (FY)	2023-12-31	$0	-$66.9M	-$58.6M	-$58.6M	—	—

3. DSGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DSGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DSGN compare to GYRE and WVE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DSGN?

Where is DSGN trading relative to its 50-day, 200-day, and 52-week technical levels?

DSGN last traded at $10.68 (-3.44% on volume of 249,553 shares), positioning the stock -15.10% below its 50-day simple moving average ($12.58) and -12.24% below its 200-day simple moving average ($12.17). Across its 52-week range of $6.16 to $17.25, DSGN sits at the 40.8% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.35 to $12.01).

DSGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DSGN's 12-month stock price target?

Design Therapeutics Inc. (DSGN) carries a 12-month consensus base price target of $9.57 (-10.4% from $10.68), with a bull-case target of $18.11 and a bear-case floor of $7.46.

Is DSGN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates DSGN D- (Sell — SELL) with an RQD Confidence score of 35/100.

Direct Sub-Reports: DSGN RQD Cockpit DSGN 12M Forecast DSGN Earnings & Move DSGN Dividends & DRIP DSGN Insiders & 13F DSGN Whale Options DSGN Profit Sankey DSGN News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DSGN — Design Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:33:46Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DSGN scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -32.1%; FCF yield -7.88%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 26; Piotroski F 2/9; Debt/Equity 0.5).

The lowest-scoring pillars are Insider Conviction and Fundamental Cash Engine. For a prospective investor, the score signals that the company is not currently generating cash from operations and that its negative ROIC and FCF yield put the equity valuation on expectations of future clinical or regulatory outcomes rather than current earnings. The Forensic Balance Sheet pillar is the relative bright spot, with a high Altman Z-Score and modest Debt/Equity, which suggests balance-sheet risk is comparatively contained. The Piotroski F-Score of 2/9 is weak, however. The Whale 13F Flow pillar is moderate, and the Insider Conviction pillar is low, which means the source data does not show strong insider-led confidence. Upside drivers would depend on events not quantified in the source data; valuation tradeoffs are that the stock trades without positive earnings to anchor a multiple. This brief is educational and not personalized financial advice.

Business

Per the profile, Design Therapeutics Inc. (DSGN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company has a market capitalization of $0.7B. Per the profile, the source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M in each financial period provided.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-79.5M	$-69.8M	N/A	$-54.6M	$16.9M	N/A
FY 2024	$0.0M	$-62.4M	$-49.6M	N/A	$-43.4M	$22.6M	N/A
FY 2023	$0.0M	$-78.2M	$-66.9M	N/A	$-58.6M	N/A	N/A

Per the SEC financials, reported revenue is $0.0M across the three periods, with operating losses of $-79.5M (FY 2025), $-62.4M (FY 2024), and $-78.2M (FY 2023). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -32.1%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash was $16.9M at FY 2025 and $22.6M at FY 2024, with FCF of $-54.6M and $-43.4M respectively.

Recent Catalysts & News Wire Analysis

Seeking Alpha (YELLOW, MARKET WIRE): Headline references a "Hold" recommendation on DT-216P2 with registrational FA plans for Q4 2026 and 12-week results in Q1 2027.
Yahoo Finance Singapore (YELLOW, MARKET WIRE): A seasonal returns chart for DSGN; no further detail in source data.
Simply Wall St (GREEN, CATALYST): Headline frames DSGN as a company "in a position to invest in growth"; the source does not provide specifics.
TradingView (RED, RISK WATCH): Headline references Oppenheimer's fall 2026 SMID-cap ideas including four Strong Buy stocks; the source does not state whether DSGN is among them, and the item is flagged as a risk watch.
Yahoo Finance Australia (YELLOW, MARKET WIRE): Item concerns Cullinan Therapeutics (CGEM) and is tagged to DSGN; no further detail in source data.
Stock Titan (YELLOW, MARKET WIRE): Item concerns Iambic Therapeutics (IAM); no further detail in source data.

The butterfly supply-chain graph reports a supply_chain value of NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the specific clinical data, timelines, and regulatory milestones for DT-216P2, and how do they relate to the Q4 2026 and Q1 2027 timing referenced in the news wire?
Why are revenue and gross margin reported as $0.0M and 0%, and what is the company's path to any revenue or cash generation?
What are the current debt obligations, given that debt is reported as N/A while Debt/Equity is 0.5?
What is the FY 2026 cash position and runway, since the latest reported cash is FY 2025's $16.9M against a $-54.6M FCF?
What are the P/E, EPS, and EV/EBITDA figures, which the source data does not provide despite the company's reported losses?

DSGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Design Therapeutics Inc. (DSGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DSGN Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 7h ago

Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027

Seeking Alpha report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 10h ago

Design Therapeutics, Inc. (DSGN) Seasonal returns chart - Yahoo Finance

Yahoo Finance Singapore report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 13h ago

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 16h ago

Oppenheimer's fall 2026 SMID-cap ideas include four Strong Buy stocks

TradingView report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 19h ago

Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history

Yahoo Finance Australia report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

Iambic Therapeutics (IAM) Stock Price, News & Analysis

Stock Titan report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Design Therapeutics (DSGN) Rallies 4.32% to $11.10, Pressing Toward Upper Resistance - Exhaustion Gap

https://www.siam.in/ report covering Design Therapeutics Inc. (DSGN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DSGN Bull vs. Bear Conversation Board — What's Your Call at $10.68?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DSGN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $9.73 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DSGN (D- • RQD 35/100) a Buy at $11.06?

Welcome to the DSGN (Design Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.74 (-21.0%)

Spot @ $11.06

Pump the brakes on DSGN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DSGN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Design Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.16 (+19.0%)

Spot @ $11.06

DSGN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DSGN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.06 (52-wk range $6.16 - $17.25), any beat on forward guidance forces shorts and underweight funds to chase.